Management of ADHD Patient Insisting on Stimulant Medication

Assessment and Diagnosis

The American Academy of Child and Adolescent Psychiatry recommends conducting a thorough psychiatric evaluation, including detailed history, collateral information, documentation of target symptoms, and mental status examination, before prescribing stimulants to patients with ADHD 1
Gathering information from at least two adult sources about the patient's symptoms, preferably from different settings, is essential for accurate diagnosis 1
Patients must meet DSM criteria for ADHD with moderate to severe impairment in at least two different settings to be considered for stimulant treatment, as per the American Academy of Child and Adolescent Psychiatry 1, 2

The American Academy of Child and Adolescent Psychiatry suggests that only patients with moderate to severe impairment in two different settings should be considered for stimulant treatment, with an effect size of approximately 1.0 compared to 0.7 for non-stimulants 1, 5
Stimulant trials should begin with low doses, such as 5 mg for methylphenidate or 2.5 mg for amphetamine/dextroamphetamine, with close monitoring and follow-up at least monthly until symptoms stabilize, as recommended by the American Academy of Child and Adolescent Psychiatry 4

The American Academy of Pediatrics recommends considering prescribing stimulant medications with less abuse potential, such as lisdexamfetamine or OROS methylphenidate, and monitoring symptoms and prescription-refill requests for signs of misuse or diversion 3
Frequent follow-up appointments during initial titration and regular monitoring of symptoms and prescription-refill requests are crucial for mitigating risks associated with stimulant use, as suggested by the American Academy of Child and Adolescent Psychiatry 4

Atomoxetine provides "around-the-clock" effects without the rebound/crash experienced with stimulants, according to Pharmacology and Therapeutics 6
Extended-release guanfacine or clonidine are alternatives with less abuse potential, as recommended by the American Academy of Pediatrics 3, 8

The American Academy of Child and Adolescent Psychiatry recommends maintaining weekly contact by telephone during initial titration and scheduling follow-up appointments at least monthly until symptoms stabilize 4
Systematically assessing for side effects, including insomnia, anorexia, headaches, social withdrawal, tics, and weight loss, and monitoring vital signs and growth parameters at each visit, is essential for ensuring patient safety, as suggested by the American Academy of Child and Adolescent Psychiatry 4

Young adults with ADHD have a higher risk for substance use disorders, requiring careful monitoring when prescribing stimulants, as recommended by the American Academy of Pediatrics 3
Considering medication coverage for symptom control during driving and educating patients about proper medication use and risks of misuse or diversion are crucial for young adults with ADHD, as suggested by the American Academy of Pediatrics 3